Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,689 recruiting studies in this area right now.
By phase
- Not applicable9,836
- Phase 24,475
- Phase 12,738
- Phase 1/Phase 21,689
- Phase 31,406
- Phase 2/Phase 3282
- Phase 4263
Top conditions
- Breast Cancer1,231
- Prostate Cancer659
- Cancer658
- Colorectal Cancer495
- Lung Cancer430
- Ovarian Cancer338
- Multiple Myeloma330
- Gastric Cancer300
- Pancreatic Cancer298
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma286
- Solid Tumor258
- Advanced Solid Tumor256
- Cervical Cancer233
- Head and Neck Cancer229
- Endometrial Cancer205
- Advanced Solid Tumors196
- Esophageal Cancer195
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University312
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- National Cancer Institute (NCI)288
- Mayo Clinic236
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca132
- University Health Network, Toronto126
Where studies are running
- California1,427
- Texas642
- Arizona513
- Florida443
- Alabama421
- New York412
- Massachusetts340
- Maryland328
- New Jersey268
- Pennsylvania240
Recruiting studies20,689 total
- NCT05768919RecruitingPhase 1/Phase 2
Liposomal curcumin with radiation and temozolomide for new brain cancer
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New Haven, ConnecticutAges 18 years+ - NCT05769010RecruitingPhase 2
HER2-positive or low breast cancer brain metastasis drug study
This Phase 2 study tests SHR-A1811 in people with HER2-positive (or HER2-low) advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and control the cancer in the brain, especially when there was no need for urgent local treatment like radiation or surgery.
Zhengzhou, HenanAges 18–75 - NCT05769660RecruitingPhase 1
Study BEY1107 plus temozolomide for recurrent glioblastoma
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
SeoulAges 19 years+ - NCT05770037RecruitingPhase 2/Phase 3
Alectinib for ALK-positive cancers in teens and adults
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
BelfastAges Any age - NCT05770102RecruitingPhase 2/Phase 3
Atezolizumab for cancers with high mutation or immune markers
This trial tests atezolizumab, a cancer immunotherapy, for people whose tumors have high mutation levels (TMB), or are “MSI-high,” or have CMMRD. It may help shrink cancer or slow its growth by boosting the immune system’s ability to recognize the tumor.
BelfastAges Any age - NCT05770531RecruitingPhase 2
Blood test guides chemo changes for metastatic breast cancer
This Phase 2 study uses a blood test that looks for “circulating tumor DNA” to help decide if standard chemotherapy should be changed. It aims to see whether this approach improves how well treatment works for certain metastatic (stage IV) breast cancers.
Nashville, TennesseeAges 18 years+ - NCT05770544RecruitingPhase 2/Phase 3
Entrectinib for ROS1 fusion cancers with matching gene test
This trial studies entrectinib, a targeted pill, in people whose cancer has a specific gene change called ROS1 fusion. It may help by shrinking tumors that depend on this ROS1 gene switch, and the study requires starting with a new tissue sample and treatment monitoring.
BelfastAges Any age - NCT05772390RecruitingPhase 2
Second radiation for a small breast cancer return
This Phase 2 study tests whether giving targeted radiation again to the same breast can control a small, local breast cancer that came back after prior whole-breast radiation. It may help some patients avoid or delay further treatment for the breast while carefully checking safety.
Meldola, Forlì CesenaAges 18 years+ - NCT05771181RecruitingPhase 2
Test vitamin E plus two cancer drugs for metastatic colon cancer
This trial tests whether adding vitamin E to two cancer medicines (fruityquintinib and tislelizumab) can work better in people with metastatic colorectal cancer that is mismatch-repair stable (MSS). It may help if your cancer has grown despite standard treatment, and you can meet the study’s safety and blood/organ requirements.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05772559Recruiting
Study of AML genes and drug response in young patients
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
AmiensAges Up to 25 years - NCT05772208RecruitingPhase 3
New treatment plan for nasopharyngeal cancer after EBV DNA stays detectable
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05772481Recruiting
PET-MRI scan test for rectal cancer after pre-surgery treatment
This study looks at whether a special scan called PET-MRI can better show how rectal cancer responds to treatment given before surgery. If it works well, it could help doctors plan the right next steps after chemoradiotherapy.
StrasbourgAges 18–75 - NCT05772923Recruiting
Testing rectal cancer organ-preservation after radiation
This trial compares two ways to preserve the rectum/avoid major surgery after radiation: a focused contact x-ray treatment versus waiting longer and then removing only a small area if needed. It may help some people keep more normal bowel function while still controlling the cancer.
Nijmegen, GelderlandAges 18 years+ - NCT05773040RecruitingPhase 1
CAR T-cell therapy made from your own immune cells
This Phase 1 trial tests an “autologous” CAR T-cell treatment (made from your own T cells) that targets a cancer marker called CD79b in certain relapsed or hard-to-treat B-cell lymphomas. It’s designed to find a safe dose and see whether the treatment can shrink tumors and help control the lymphoma after prior therapies.
Houston, TexasAges 18 years+ - NCT05773144Recruiting
Exercise program during chemotherapy for colon cancer recovery
This trial tests an aerobic exercise plan during chemotherapy for people with stage II or III colon cancer. It compares different exercise approaches to see if exercise can be done safely and may improve how you tolerate treatment and recovery.
Oakland, CaliforniaAges 18 years+ - NCT05773859RecruitingPhase 1/Phase 2
Vaccination before surgery to treat advanced ovarian cancer
This trial studies a vaccine made from your immune cells (dendritic cell vaccine) given before chemotherapy and surgery. It aims to help your body recognize and fight ovarian cancer more effectively in people whose cancer is advanced and spread.
Nijmegen, GelderlandAges 18 years+ - NCT05775146RecruitingPhase 2
Radiation to liver metastases after colon cancer treatment
This trial studies giving targeted high-dose radiation (SBRT) to liver metastases from colorectal cancer after initial treatment, with the goal of improving long-term control or cure. It may help people who have a limited number of liver spots that doctors think can be treated safely and effectively.
Edmonton, AlbertaAges 18 years+ - NCT05774483Recruiting
Check nodes in early mouth cancer using a biopsy or planned neck surgery
This trial studies two ways to check whether early oral cavity cancer has spread to nearby neck lymph nodes. It compares sentinel node biopsy versus limited elective neck dissection to see which approach is more useful for people with node-negative tongue or inner-cheek cancers.
Mumbai, MaharashtraAges 18–80 - NCT05774678RecruitingPhase 3
Pre-surgery radiation options for invasive breast cancer
This trial compares two schedules of radiation given before mastectomy to see which works better for invasive breast cancer, followed by immediate breast reconstruction. It also studies tiny “biomarker” signals in tissue to learn why one radiation approach may help more.
Houston, TexasAges 18 years+ - NCT05774561Recruiting
Using blood tests to monitor HPV-related cancer treatment
This study checks whether “liquid biopsies” (blood tests that look for cancer-related signals) can help monitor how HPV-related cancers respond to treatment. It may help doctors spot changes earlier during care.
OlomoucAges 18–99 - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Birmingham, AlabamaAges 18–130 - NCT05775419Recruiting
Chemo and radiation, with or without extra chemo after
This trial compares standard chemo plus radiation versus the same treatment plus extra “consolidation” chemo afterward. It’s for people with a type of esophageal cancer that can’t be removed with surgery, to see if the added treatment works better and is still safe.
Nanjing, JiangsuAges 18–70 - NCT05775458Recruiting
Study of treatments for aggressive brain tumor cell damage
This study looks at glioblastoma (GBM), a very aggressive brain tumor, and how “brain cell overload” (glutamate excitotoxicity) may affect tumor growth. It focuses on adults who are planned for complete tumor removal, followed by standard radiation and chemotherapy.
Milan, MilanAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,689 recruiting oncology studies from the U.S. registry right now, out of 31,955 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.